RT Journal Article
T1 Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease.
A1 Gallego-Durán, Rocío
A1 Cerro-Salido, Pablo
A1 Gomez-Gonzalez, Emilio
A1 Pareja, María Jesús
A1 Ampuero, Javier
A1 Rico, María Carmen
A1 Aznar, Rafael
A1 Vilar-Gomez, Eduardo
A1 Bugianesi, Elisabetta
A1 Crespo, Javier
A1 González-Sánchez, Francisco José
A1 Aparcero, Reyes
A1 Moreno, Inmaculada
A1 Soto, Susana
A1 Arias-Loste, María Teresa
A1 Abad, Javier
A1 Ranchal, Isidora
A1 Andrade, Raúl Jesús
A1 Calleja, Jose Luis
A1 Pastrana, Miguel
A1 Lo Iacono, Oreste
A1 Romero-Gómez, Manuel
K1 Área bajo la curva
K1 Biopsia
K1 Espectroscopía de resonancia magnética
K1 Curva ROC
K1 Biomarcadores
K1 Esteatosis hepática no alcohólica
AB There is a need, in NAFLD management, to develop non-invasive methods to detect steatohepatitis (NASH) and to predict advanced fibrosis stages. We evaluated a tool based on optical analysis of liver magnetic resonance images (MRI) as biomarkers for NASH and fibrosis detection by investigating patients with biopsy-proven NAFLD who underwent magnetic resonance (MR) protocols using 1.5T General Electric (GE) or Philips devices. Two imaging biomarkers (NASHMRI and FibroMRI) were developed, standardised and validated using area under the receiver operating characteristic curve (AUROC) analysis. The results indicated NASHMRI diagnostic accuracy for steatohepatitis detection was 0.83 (95% CI: 0.73-0.93) and FibroMRI diagnostic accuracy for significant fibrosis determination was 0.85 (95% CI: 0.77-0.94). These findings were independent of the MR system used. We conclude that optical analysis of MRI has high potential to define non-invasive imaging biomarkers for the detection of steatohepatitis (NASHMRI) and the prediction of significant fibrosis (FibroMRI) in NAFLD patients.
PB Nature Publishing Group
YR 2016
FD 2016-08-12
LK http://hdl.handle.net/10668/2426
UL http://hdl.handle.net/10668/2426
LA en
NO Gallego-Durán R, Cerro-Salido P, Gomez-Gonzalez E, Pareja MJ, Ampuero J, Rico MC, et al. Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. Sci Rep. 2016; 6:31421
NO Journal Article;
DS RISalud
RD Apr 18, 2025